JP2022548057A5 - - Google Patents
Info
- Publication number
- JP2022548057A5 JP2022548057A5 JP2022516173A JP2022516173A JP2022548057A5 JP 2022548057 A5 JP2022548057 A5 JP 2022548057A5 JP 2022516173 A JP2022516173 A JP 2022516173A JP 2022516173 A JP2022516173 A JP 2022516173A JP 2022548057 A5 JP2022548057 A5 JP 2022548057A5
- Authority
- JP
- Japan
- Prior art keywords
- nrg1
- amino acid
- acid sequence
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025112447A JP2025143396A (ja) | 2019-09-11 | 2025-07-02 | Her3抗原結合性分子を使用したがんの処置および予防 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1913079.8A GB201913079D0 (en) | 2019-09-11 | 2019-09-11 | Treatment and prevention of cancer using her3 antigen-binding molecules |
| GB1913079.8 | 2019-09-11 | ||
| PCT/EP2020/075319 WO2021048274A1 (en) | 2019-09-11 | 2020-09-10 | Treatment and prevention of cancer using her3 antigen-binding molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025112447A Division JP2025143396A (ja) | 2019-09-11 | 2025-07-02 | Her3抗原結合性分子を使用したがんの処置および予防 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548057A JP2022548057A (ja) | 2022-11-16 |
| JP2022548057A5 true JP2022548057A5 (cg-RX-API-DMAC7.html) | 2023-09-19 |
| JP7708741B2 JP7708741B2 (ja) | 2025-07-15 |
Family
ID=68241208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516173A Active JP7708741B2 (ja) | 2019-09-11 | 2020-09-10 | Her3抗原結合性分子を使用したがんの処置および予防 |
| JP2025112447A Pending JP2025143396A (ja) | 2019-09-11 | 2025-07-02 | Her3抗原結合性分子を使用したがんの処置および予防 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025112447A Pending JP2025143396A (ja) | 2019-09-11 | 2025-07-02 | Her3抗原結合性分子を使用したがんの処置および予防 |
Country Status (16)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3023551T3 (en) | 2016-03-25 | 2025-06-02 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
| CN109563166B (zh) * | 2016-04-28 | 2022-12-20 | 拜奥穆尼克斯制药 | 靶向egfr和her2的双特异性抗体 |
| AU2018241881B2 (en) | 2017-03-27 | 2024-10-10 | Biomunex Pharmaceuticals | Stable multispecific antibodies |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| GB201913079D0 (en) * | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
| CN114790462B (zh) * | 2021-01-25 | 2023-10-31 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向bcma的嵌合抗原受体及其应用 |
| CN112961865B (zh) * | 2021-02-22 | 2023-06-02 | 广西大学 | 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用 |
| WO2022192534A1 (en) * | 2021-03-11 | 2022-09-15 | Elevation Oncology, Inc. | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions |
| TW202313972A (zh) * | 2021-06-03 | 2023-04-01 | 荷蘭商美勒斯公司 | 新nrg1融合物、融合接合處及檢測彼等之方法 |
| WO2022255869A2 (en) * | 2021-06-03 | 2022-12-08 | Merus N.V. | Liquid biopsy assays for detecting nrg1 fusion polynucleotides |
| GB202108449D0 (en) | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing her3 antigen-binding molecules |
| JP2024529141A (ja) | 2021-08-13 | 2024-08-01 | ハミングバード・バイオサイエンス・プライベート・リミテッド | Her3抗原結合性分子を使用したがんの処置および予防 |
| CN118541395A (zh) * | 2021-09-03 | 2024-08-23 | 癌症研究科技有限公司 | 用her3抗原结合分子治疗和预防癌症 |
| CN116333118B (zh) * | 2021-12-16 | 2024-04-19 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
| IL315262A (en) * | 2022-03-03 | 2024-10-01 | Pfizer | Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses |
| WO2024121163A1 (en) | 2022-12-06 | 2024-06-13 | Cancer Research Technology Limited | Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers |
| WO2024121226A1 (en) | 2022-12-07 | 2024-06-13 | Hummingbird Bioscience Pte. Ltd. | Combination for treatment and prevention of cancer |
| CN120857946A (zh) | 2023-01-03 | 2025-10-28 | 蜂鸟生物科技私人有限公司 | Her3结合抗体-药物缀合物 |
| KR20260026009A (ko) | 2023-04-06 | 2026-02-25 | 허밍버드 바이오사이언스 피티이. 엘티디. | Her3 항원 결합 분자를 이용한 암의 치료 및 예방 |
| KR20260022498A (ko) | 2023-04-14 | 2026-02-19 | 허밍버드 바이오사이언스 피티이. 엘티디. | 암의 치료 및 예방을 위한 조합물 |
| WO2025057173A2 (en) * | 2023-09-14 | 2025-03-20 | B.G. Negev Technologies And Applications Ltd. | Ligand-based chimeric antigen receptors and uses thereof |
| CN122206706A (zh) | 2023-09-15 | 2026-06-12 | 蜂鸟生物科技私人有限公司 | 使用her3结合分子治疗和预防癌症 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| KR20150036824A (ko) * | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-her 항체 |
| US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
| EP2788382A2 (en) | 2011-12-05 | 2014-10-15 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| WO2013148315A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US10239951B2 (en) * | 2013-05-08 | 2019-03-26 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
| US20160319253A1 (en) | 2013-12-19 | 2016-11-03 | National Cancer Center | Novel fusion genes as factors responsible for gastric cancer |
| WO2016059602A2 (en) * | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
| JP7737220B2 (ja) | 2017-03-31 | 2025-09-10 | メルス ナムローゼ フェンノートシャップ | NRG1融合遺伝子を有する細胞の処置における使用のためのErbB-2及びErbB3結合二重特異性抗体 |
| CN111527103A (zh) | 2017-09-08 | 2020-08-11 | 科罗拉多大学董事会,法人团体 | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| GB201913079D0 (en) * | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
-
2019
- 2019-09-11 GB GBGB1913079.8A patent/GB201913079D0/en not_active Ceased
-
2020
- 2020-09-10 EP EP21180956.1A patent/EP3943509A1/en active Pending
- 2020-09-10 WO PCT/EP2020/075319 patent/WO2021048274A1/en not_active Ceased
- 2020-09-10 PT PT207805722T patent/PT3818086T/pt unknown
- 2020-09-10 PL PL20780572T patent/PL3818086T3/pl unknown
- 2020-09-10 MX MX2022002977A patent/MX2022002977A/es unknown
- 2020-09-10 ES ES20780572T patent/ES2896921T3/es active Active
- 2020-09-10 EP EP20780572.2A patent/EP3818086B1/en active Active
- 2020-09-10 CA CA3149853A patent/CA3149853A1/en active Pending
- 2020-09-10 KR KR1020227011181A patent/KR20220086554A/ko active Pending
- 2020-09-10 JP JP2022516173A patent/JP7708741B2/ja active Active
- 2020-09-10 CN CN202080009114.6A patent/CN113347994B/zh active Active
- 2020-09-10 TW TW109131184A patent/TWI883044B/zh active
- 2020-09-10 BR BR112022004474A patent/BR112022004474A8/pt unknown
- 2020-09-10 DK DK20780572.2T patent/DK3818086T3/da active
- 2020-09-10 AU AU2020347473A patent/AU2020347473B2/en active Active
- 2020-09-10 CN CN202211117480.0A patent/CN116059347A/zh active Pending
-
2021
- 2021-01-20 US US17/153,705 patent/US11208498B2/en active Active
- 2021-11-24 US US17/535,313 patent/US20220153870A1/en not_active Abandoned
-
2025
- 2025-07-02 JP JP2025112447A patent/JP2025143396A/ja active Pending
- 2025-08-15 US US19/301,118 patent/US20260132219A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533957A5 (cg-RX-API-DMAC7.html) | ||
| Nishioka et al. | Lysyl oxidase: from basic science to future cancer treatment | |
| IL270852A (en) | Molecules that bind at the site of egfr and c – met - fibronectin type iii | |
| Yaffee et al. | Review of systemic therapies for locally advanced and metastatic rectal cancer | |
| Monk et al. | Anti-angiogenesis agents in metastatic or recurrent cervical cancer | |
| JP2022088662A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Molecular mechanisms of chemoresistance in oral cancer | |
| EP4512478A3 (en) | Treatment of cancer | |
| JP2011521618A5 (cg-RX-API-DMAC7.html) | ||
| RU2007132876A (ru) | Антитела к dr5 и их применения | |
| JP2017503480A5 (cg-RX-API-DMAC7.html) | ||
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| RU2019143403A (ru) | Комбинированные терапии для лечения онкологических заболеваний | |
| JP2024536719A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer | |
| Gafton et al. | Hepatocellular carcinoma: insight in the biological treatment beyond sorafenib | |
| Le Bourhis et al. | Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications | |
| JP2022551495A5 (cg-RX-API-DMAC7.html) | ||
| RU2015154985A (ru) | Способы лечения рака | |
| RU2019134769A (ru) | Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения | |
| JP2025508695A5 (cg-RX-API-DMAC7.html) | ||
| Akent'eva et al. | Effects of RHAMM/HMMR-selective peptides on survival of breast cancer cells | |
| Rajabi et al. | DLEU1 as a key regulator in glioblastoma: A review of ferroptosis resistance, tumor microenvironment interactions, and emerging RNA-based therapeutic strategies | |
| Chetia et al. | From unearthing to an intriguing cancer-fighting target: the human BCL-2 promoter G-quadruplex and i-motif. | |
| Radford et al. | Targeted and immunotherapy approaches in HER2-positive gastric and gastroesophageal junction adenocarcinoma: a new era |